Cavitary lung lesions caused by in a patient with myelofibrosis on ruxolitinib.

Austin Ritter, Nicholas Kensey, James Higgs, Hadeel Zainah
Author Information
  1. Austin Ritter: Kent Hospital Internal Medicine, Brown University, Warwick, Rhode Island, USA austin.ritter@gmail.com. ORCID
  2. Nicholas Kensey: Kent Hospital Internal Medicine, Brown University, Warwick, Rhode Island, USA.
  3. James Higgs: Department of Infectious Diseases, Kent Hospital, Warwick, Rhode Island, USA.
  4. Hadeel Zainah: Department of Infectious Diseases, Kent Hospital, Warwick, Rhode Island, USA.

Abstract

We report a rare case of a patient with Janus kinase 2-positive myelofibrosis on ruxolitinib, presenting with indolent pneumonia and cavitary lung lesions. Initial transthoracic biopsy was non-specific, but thoracoscopic biopsy revealed necrotising granulomatous disease caused by pneumonia (PJP). The patient, initially treated with trimethoprim-sulfamethoxazole, was switched to atovaquone due to gastrointestinal intolerance. Given the patient's immunosuppression and extensive cavitary lesions, an extended course of atovaquone was administered, guided by serial imaging, resulting in clinical and radiological improvement. Unfortunately, the patient later passed away from a severe SARS-CoV-2 infection before complete radiographic resolution was observed. This case highlights the importance of recognising atypical PJP presentations causing granulomatous disease in immunosuppressed patients. While rare, documenting such cases may improve diagnosis using less invasive methods and help determine optimal treatment durations for resolution of these atypical infections.

Keywords

References

  1. JAMA. 2016 Dec 20;316(23):2547-2548 [PMID: 27792809]
  2. Hematol Oncol. 2018 Apr 6;: [PMID: 29624703]
  3. Immunol Lett. 2009 Dec 2;127(1):55-9 [PMID: 19733591]
  4. Clin Microbiol Infect. 2020 Sep;26(9):1137-1143 [PMID: 32479781]
  5. Clin Microbiol Infect. 2022 Jan;28(1):23-30 [PMID: 34464734]
  6. Am Rev Respir Dis. 1989 Nov;140(5):1204-9 [PMID: 2817582]
  7. Leukemia. 2019 Apr;33(4):844-862 [PMID: 30700842]
  8. Blood Cancer J. 2021 Jan 7;11(1):4 [PMID: 33414394]
  9. BMJ Case Rep. 2014 Jun 02;2014: [PMID: 24891492]
  10. BMC Infect Dis. 2021 Jan 7;21(1):27 [PMID: 33413168]
  11. Eur Respir J. 1994 Jan;7(1):134-9 [PMID: 8143812]
  12. Clin Infect Dis. 2002 Apr 15;34(8):1098-107 [PMID: 11914999]
  13. AJR Am J Roentgenol. 2012 Jun;198(6):W555-61 [PMID: 22623570]
  14. Clin Microbiol Rev. 2012 Apr;25(2):297-317 [PMID: 22491773]
  15. JAAPA. 2017 Jan;30(1):28-31 [PMID: 28033170]
  16. Mayo Clin Proc. 2007 Sep;82(9):1052-9 [PMID: 17803871]
  17. Infect Drug Resist. 2022 Jul 30;15:4149-4154 [PMID: 35937785]
  18. Cancer. 2020 Mar 15;126(6):1243-1252 [PMID: 31860137]
  19. Am J Surg Pathol. 2010 May;34(5):730-4 [PMID: 20414100]
  20. Am J Clin Pathol. 1998 Mar;109(3):335-7 [PMID: 9495208]
  21. Acta Clin Belg. 2021 Feb;76(1):75-78 [PMID: 31470765]
  22. Diagn Microbiol Infect Dis. 2013 Mar;75(3):260-5 [PMID: 23333101]
  23. Scand J Infect Dis. 1995;27(2):157-62 [PMID: 7660081]
  24. Infection. 2023 Apr;51(2):545-547 [PMID: 35718842]
  25. Microbiology (Reading). 2004 May;150(Pt 5):1173-1178 [PMID: 15133077]
  26. Cancers (Basel). 2020 Oct 26;12(11): [PMID: 33114733]
  27. Open Forum Infect Dis. 2021 Oct 29;8(12):ofab545 [PMID: 34988242]
  28. J Clin Microbiol. 2021 Jun 18;59(7):e0178420 [PMID: 33504591]
  29. Sci Rep. 2019 Aug 29;9(1):12508 [PMID: 31467367]
  30. Antimicrob Agents Chemother. 2011 Oct;55(10):4613-8 [PMID: 21788460]
  31. Respir Med Case Rep. 2020 Nov 06;31:101277 [PMID: 33209577]
  32. Clin Infect Dis. 1999 Sep;29(3):670-2 [PMID: 10530464]
  33. Clin Microbiol Rev. 2008 Apr;21(2):305-33, table of contents [PMID: 18400799]
  34. IDCases. 2017 Jul 08;10:32-34 [PMID: 28856102]
  35. Tuberc Respir Dis (Seoul). 2020 Apr;83(2):132-140 [PMID: 32185915]
  36. Infect Dis (Lond). 2018 May;50(5):381-387 [PMID: 29251529]
  37. Pathogens. 2019 Apr 04;8(2): [PMID: 30987351]
  38. BMC Infect Dis. 2019 Aug 22;19(1):739 [PMID: 31438872]
  39. Chest. 1998 May;113(5):1215-24 [PMID: 9596297]
  40. PLoS One. 2020 Dec 21;15(12):e0244023 [PMID: 33347478]

MeSH Term

Humans
Atovaquone
COVID-19
Fatal Outcome
Immunocompromised Host
Nitriles
Pneumocystis carinii
Pneumonia, Pneumocystis
Primary Myelofibrosis
Pyrazoles
Pyrimidines
SARS-CoV-2

Chemicals

Atovaquone
Nitriles
Pyrazoles
Pyrimidines
ruxolitinib

Word Cloud

Created with Highcharts 10.0.0patientpneumonialesionsrarecasemyelofibrosisruxolitinibcavitarylungbiopsygranulomatousdiseasecausedPJPatovaquoneresolutionatypicalhaematologyreportJanuskinase2-positivepresentingindolentInitialtransthoracicnon-specificthoracoscopicrevealednecrotisinginitiallytreatedtrimethoprim-sulfamethoxazoleswitchedduegastrointestinalintoleranceGivenpatient'simmunosuppressionextensiveextendedcourseadministeredguidedserialimagingresultingclinicalradiologicalimprovementUnfortunatelylaterpassedawaysevereSARS-CoV-2infectioncompleteradiographicobservedhighlightsimportancerecognisingpresentationscausingimmunosuppressedpatientsdocumentingcasesmayimprovediagnosisusinglessinvasivemethodshelpdetermineoptimaltreatmentdurationsinfectionsCavitarydrugsmedicinesinclbloodtransfusionimmunologyinfectiousdiseasesrespiratorymedicine

Similar Articles

Cited By